Volume 27, Number 8—August 2021
Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa
||Equal interest of everyone unless good reasons to justify differential prioritization
||May be most appropriate to guide allocation of scarce resources among persons or populations who can be expected to derive the same benefit from the resource (e.g., high-risk populations)
||Allocation according to capacity to do most good or minimize most harm (e.g., saving most possible lives)
||May be most appropriate to guide the allocation of scarce resources that confer substantially different benefits to different persons (e.g., groups expected to derive the most benefit)
|Prioritize highest risk
||Allocation to persons most at risk
||May be most appropriate to guide allocation of resources intended to protect those most at risk (e.g., groups most at risk for infection and severe illness)
|Prioritize those tasked with helping others||Allocation to persons with certain skills that can save others or because of their participation in helping others (e.g., vaccine trial volunteers)||May be most appropriate to guide allocation of resources to health care workers, first responders, vaccine trial participants, etc.|
*COVID-19, coronavirus disease.
- World Health Organization. WHO coronavirus disease (COVID-19) dashboard [cited 2021 May 9]. https://covid19.who.int
- Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity. Lancet. 2020;395:1527–9.
- Horton R. Offline: COVID-19-a reckoning. Lancet. 2020;395:935.
- Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020;323:2245–6.
- Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52:737–41.
- Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines: delivering protective immunity. BMJ. 2020;371:m4838.
- Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1:
- Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet. 2020;395:1595–8.
- World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines [cited 2020 Dec 20]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- World Health Organization. COVID-19 vaccines [cited 2021 May 8]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
- Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions [cited 2021 May 9]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
- World Health Organization and United Nations Children’s Fund. Progress and challenges with achieving universal immunization coverage: 2019 WHO/UNICEF estimates of national immunization coverage [cited 2020 Aug 6]. https://www.who.int/immunization/monitoring_surveillance/who-immuniz.pdf
- Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867–72.
- Mahase E. Covid-19: What do we know about the late stage vaccine candidates? BMJ. 2020;371:m4576.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15.
- Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93.
- World Health Organization. WHO target product profiles for COVID-19 vaccines [cited 2021 May 7]. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines
- Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018;40:83–94.
- van Vuuren A, Rheeder P, Hak E. Effectiveness of influenza vaccination in the elderly in South Africa. Epidemiol Infect. 2009;137:994–1002.
- World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine [cited 2021 May 9]. https://www.who.int/news/item/19-03-2021-statement-of-the-who-global-advisory-committee-on-vaccine-safety-(gacvs)-covid-19-subcommittee-on-safety-signals-related-to-the-astrazeneca-covid-19-vaccine
- World Health Organization. Global vaccine safety. Global Advisory Committee on Vaccine Safety, 27–28 May 2020 [cited 2021 May 9]. https://www.who.int/vaccine_safety/committee/reports/May_2020/en
- Nzolo D, Kuemmerle A, Lula Y, Ntamabyaliro N, Engo A, Mvete B, et al. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Ther Adv Drug Saf. 2019;10:
- Jusot V, Chimimba F, Dzabala N, Menang O, Cole J, Gardiner G, et al. Enhancing pharmacovigilance in sub-Saharan Africa through training and mentoring: a GSK pilot initiative in Malawi. [Erratum in: Drug Saf. 2021;44:723]. Drug Saf. 2020;43:583–93.
- Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010;28(Suppl 1):A18–25.
- Sarma H, Budden A, Luies SK, Lim SS, Shamsuzzaman M, Sultana T, et al. Implementation of the World’s largest measles-rubella mass vaccination campaign in Bangladesh: a process evaluation. BMC Public Health. 2019;19:925.
- Kupferschmidt K. ‘Vaccine nationalism’ threatens global plan to distribute COVID-19 shots fairly. Science [cited 2020 Aug 6]. https://www.sciencemag.org/news/2020/07/vaccine-nationalism-threatens-global-plan-distribute-covid-19-shots-fairly
- Portnoy A, Ozawa S, Grewal S, Norman BA, Rajgopal J, Gorham KM, et al. Costs of vaccine programs across 94 low- and middle-income countries. Vaccine. 2015;33(Suppl 1):A99–108.
- World Health Organization. Fair allocation mechanism for COVID-19 vaccines through the COVAX facility [cited 2021 May 9]. https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility
- Holder J. Tracking coronavirus vaccinations around the world. The New York Times. Updated 2021 May 8 [cited 2021 May 9]. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
- Mwai P. British Broadcasting Corporation. Covid-19 Africa: What is happening with vaccines? Updated 2021 April 23 [cited 2021 May 9]. https://www.bbc.com/news/56100076.
- Brew J, Sauboin C. A systematic review of the incremental costs of implementing a new vaccine in the expanded program of immunization in sub-Saharan Africa. MDM Policy Pract. 2019;4:
- Vaughan K, Ozaltin A, Mallow M, Moi F, Wilkason C, Stone J, et al. The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review. Vaccine X. 2019;2:
- Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18:119–31.
- Kalantari N, Borisch B, Lomazzi M. Vaccination—a step closer to universal health coverage. J Public Health. 2020:s10389–020–01322-y.
- World Health Organization. Global health ethics. Ethics and COVID-19: resource allocation and priority setting [cited 2021 May 8]. https://www.who.int/ethics/publications/ethics-and-covid-19-resource-allocation-and-priority-setting/en
- Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021;9:160.
- Africa Centres for Disease Control and Prevention. COVID-19 vaccine perceptions: a 15-country study [cited 2021 May 9]. https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study
- Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021;384:1775–7.
- Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;
NEJMc2104974; Epub ahead of print.
- Stranix-Chibanda L, Brummel S, Pilotto J, Mutambanengwe M, Chanaiwa V, Mhembere T, et al.; PROMISE study team. PROMISE study team. Slow acceptance of universal antiretroviral therapy (ART) among mothers enrolled in IMPAACT PROMISE studies across the globe. AIDS Behav. 2019;23:2522–31.
- Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 2007;4:
- Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315:1149–58.
- Krause NM, Freiling I, Beets B, Brossard D. Fact-checking as risk communication: the multi-layered risk of misinformation in times of COVID-19. J Risk Res. 2020;23:1052–9.
- Malecki KMC, Keating JA, Safdar N. Crisis communication and public perception of COVID-19 risk in the era of social media. Clin Infect Dis. 2021;72:697–702.
- World Health Organization. Risk communication and community engagement readiness and response to coronavirus disease (COVID-19): interim guidance. Updated 2020 March 19 [cited 2021 May 8]. https://apps.who.int/iris/bitstream/handle/10665/331513/WHO-2019-nCoV-RCCE-2020.2-eng.pdf.
- Fähnrich C, Denecke K, Adeoye OO, Benzler J, Claus H, Kirchner G, et al. Surveillance and Outbreak Response Management System (SORMAS) to support the control of the Ebola virus disease outbreak in West Africa. Euro Surveill. 2015;20:21071.
- Jobanputra K, Greig J, Shankar G, Perakslis E, Kremer R, Achar J, et al. Electronic medical records in humanitarian emergencies - the development of an Ebola clinical information and patient management system. F1000 Res. 2016;5:1477.
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–4.
- Mpofu M, Semo BW, Grignon J, Lebelonyane R, Ludick S, Matshediso E, et al. Strengthening monitoring and evaluation (M&E) and building sustainable health information systems in resource limited countries: lessons learned from an M&E task-shifting initiative in Botswana. BMC Public Health. 2014;14:1032.
- World Health Organization. Overview of VPD surveillance principles [cited 2021 May 8]. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_01_Overview_R2.pdf
Page created: May 27, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.